476 related articles for article (PubMed ID: 26011143)
1. Riociguat: a novel new drug for treatment of pulmonary hypertension.
Makowski CT; Rissmiller RW; Bullington WM
Pharmacotherapy; 2015 May; 35(5):502-19. PubMed ID: 26011143
[TBL] [Abstract][Full Text] [Related]
2. Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Bishop BM
Am J Health Syst Pharm; 2014 Nov; 71(21):1839-44. PubMed ID: 25320133
[TBL] [Abstract][Full Text] [Related]
3. Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.
Lian TY; Jiang X; Jing ZC
Drug Des Devel Ther; 2017; 11():1195-1207. PubMed ID: 28458514
[TBL] [Abstract][Full Text] [Related]
4. Riociguat, an oral soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.
Belik J
Curr Opin Investig Drugs; 2009 Sep; 10(9):971-9. PubMed ID: 19705340
[TBL] [Abstract][Full Text] [Related]
5. Riociguat for the treatment of pulmonary hypertension.
Hambly N; Granton J
Expert Rev Respir Med; 2015; 9(6):679-95. PubMed ID: 26599488
[TBL] [Abstract][Full Text] [Related]
6. Soluble guanylate cyclase stimulators in pulmonary hypertension.
Stasch JP; Evgenov OV
Handb Exp Pharmacol; 2013; 218():279-313. PubMed ID: 24092345
[TBL] [Abstract][Full Text] [Related]
7. [Riociguat: stimulator of soluble guanylate-cyclase. New mode of action for the treatment of pulmonary arterial and non operable chronic thromboembolic pulmonary hypertension].
Leuchte HH; Behr J; Ewert R; Ghofrani HA; Grünig E; Halank M; Held M; Klose H; Rosenkranz S; Schermuly RT; Wilkens H; Hoeper MM
Pneumologie; 2015 Mar; 69(3):135-43. PubMed ID: 25750094
[TBL] [Abstract][Full Text] [Related]
8. Riociguat for the treatment of pulmonary hypertension.
Meis T; Behr J
Expert Opin Pharmacother; 2014 Nov; 15(16):2419-27. PubMed ID: 25260791
[TBL] [Abstract][Full Text] [Related]
9. Riociguat: a novel therapeutic option for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Mielniczuk LM; Swiston JR; Mehta S
Can J Cardiol; 2014 Oct; 30(10):1233-40. PubMed ID: 25154043
[TBL] [Abstract][Full Text] [Related]
10. Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Dasgupta A; Bowman L; D'Arsigny CL; Archer SL
Clin Pharmacol Ther; 2015 Jan; 97(1):88-102. PubMed ID: 25670386
[TBL] [Abstract][Full Text] [Related]
11. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study.
Ghofrani HA; Hoeper MM; Halank M; Meyer FJ; Staehler G; Behr J; Ewert R; Weimann G; Grimminger F
Eur Respir J; 2010 Oct; 36(4):792-9. PubMed ID: 20530034
[TBL] [Abstract][Full Text] [Related]
12. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2).
Simonneau G; D'Armini AM; Ghofrani HA; Grimminger F; Hoeper MM; Jansa P; Kim NH; Wang C; Wilkins MR; Fritsch A; Davie N; Colorado P; Mayer E
Eur Respir J; 2015 May; 45(5):1293-302. PubMed ID: 25395036
[TBL] [Abstract][Full Text] [Related]
13. Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Marra AM; Egenlauf B; Ehlken N; Fischer C; Eichstaedt C; Nagel C; Bossone E; Cittadini A; Halank M; Gall H; Olsson KM; Lange TJ; Grünig E
Int J Cardiol; 2015 Sep; 195():19-26. PubMed ID: 26011408
[TBL] [Abstract][Full Text] [Related]
14. Individual dose adjustment of riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Hill NS; Rahaghi FF; Sood N; Frey R; Ghofrani HA
Respir Med; 2017 Aug; 129():124-129. PubMed ID: 28732819
[TBL] [Abstract][Full Text] [Related]
15. Riociguat for the treatment of pulmonary hypertension: a safety evaluation.
Binder C; Zotter-Tufaro C; Bonderman D
Expert Opin Drug Saf; 2016 Dec; 15(12):1671-1677. PubMed ID: 27750459
[TBL] [Abstract][Full Text] [Related]
16. Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Results from a phase II long-term extension study.
Halank M; Hoeper MM; Ghofrani HA; Meyer FJ; Stähler G; Behr J; Ewert R; Fletcher M; Colorado P; Nikkho S; Grimminger F
Respir Med; 2017 Jul; 128():50-56. PubMed ID: 28610669
[TBL] [Abstract][Full Text] [Related]
17. Riociguat for the treatment of pulmonary hypertension.
Schermuly RT; Janssen W; Weissmann N; Stasch JP; Grimminger F; Ghofrani HA
Expert Opin Investig Drugs; 2011 Apr; 20(4):567-76. PubMed ID: 21391889
[TBL] [Abstract][Full Text] [Related]
18. Riociguat for pulmonary hypertension.
Ghofrani HA; Voswinckel R; Gall H; Schermuly R; Weissmann N; Seeger W; Grimminger F
Future Cardiol; 2010 Mar; 6(2):155-66. PubMed ID: 20230258
[TBL] [Abstract][Full Text] [Related]
19. Riociguat: first global approval.
Conole D; Scott LJ
Drugs; 2013 Nov; 73(17):1967-75. PubMed ID: 24218053
[TBL] [Abstract][Full Text] [Related]
20. [The achievements of the modern specific therapy of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: focus on the stimulator of soluble guanylate cyclase riociguat].
Gratsianskaya SE; Valieva ZS; Martynyuk TV
Ter Arkh; 2020 Oct; 92(9):77-84. PubMed ID: 33346435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]